The White House withdrew Heidi Overton’s nomination to lead the FDA on November 17, 2026, one day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on advancing her to the full Senate. The decision followed bipartisan opposition, including from committee chair Sen. Bill Cassidy over Overton’s involvement in childhood vaccine policy changes and questions about her experience. Overton, a physician and White House domestic policy official nominated in August after serving at the America First Policy Institute, faced additional scrutiny on mifepristone access, vaping policy, and abortion-related positions during her September confirmation hearing. With Democrats set to control the Senate after January, the withdrawal leaves the agency under an acting commissioner and removes any near-term path to confirmation.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড1H6H1D7D30DALL
View resolved

বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা